tsg 101 Activators
Tsg101, or Tumor susceptibility gene 101, plays a pivotal role in cellular processes such as endosomal sorting and vesicle trafficking. As part of the endosomal sorting complex required for transport (ESCRT) machinery, Tsg101 is integral to the formation of multivesicular bodies (MVBs) and subsequent protein sorting and degradation through the endolysosomal pathway. This protein serves as a key regulator of various signaling pathways by facilitating the sorting of ubiquitinated membrane proteins into intraluminal vesicles for lysosomal degradation, thereby controlling cellular homeostasis and signaling dynamics.
Activation of Tsg101 is primarily regulated by post-translational modifications and protein-protein interactions. Phosphorylation events and ubiquitination play essential roles in modulating the activity and localization of Tsg101 within the cell. Additionally, interactions with other ESCRT components and accessory proteins further regulate Tsg101 function and recruitment to specific cellular compartments. Importantly, the activation of Tsg101 is tightly regulated to ensure proper endosomal sorting and vesicle trafficking, thereby maintaining cellular integrity and function. Dysregulation of Tsg101 activation has been implicated in various diseases, highlighting its significance in cellular physiology and pathology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. TSG101 is involved in endosomal sorting complexes required for transport (ESCRT) machinery. Bortezomib enhances TSG101 activity by preventing its degradation through the proteasomal pathway, leading to increased functional activity in mediating endosomal sorting. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine is an autophagy inhibitor. TSG101 is implicated in the autophagic process. Inhibition of autophagy by Chloroquine enhances TSG101 functional activity by preventing its turnover through the autophagic pathway, resulting in increased efficacy in cellular processes related to autophagy. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor. Similar to Bortezomib, MG-132 enhances TSG101 activity by blocking its degradation via the proteasomal pathway. This leads to increased functional activity of TSG101 in mediating endosomal sorting within the ESCRT machinery. | ||||||
FCM Lysing solution (1x) | sc-3621 | 150 ml | $62.00 | 8 | ||
Ammonium Chloride is a lysosome inhibitor. TSG101 is involved in lysosomal targeting and degradation processes. Inhibition of lysosomal function by Ammonium Chloride enhances TSG101 activity by preventing its degradation within lysosomes, resulting in increased functional activity in mediating cellular processes associated with lysosomal targeting. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin is a protease inhibitor. TSG101 is susceptible to proteolytic degradation. Leupeptin enhances TSG101 activity by inhibiting proteases, preventing TSG101 degradation, and thereby increasing its functional activity in various cellular processes related to endosomal sorting and protein trafficking. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is an autophagy inhibitor. Similar to Chloroquine, 3-Methyladenine enhances TSG101 functional activity by blocking the autophagic process. This prevents turnover and degradation of TSG101, leading to increased efficacy in cellular processes associated with autophagy. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin is a proteasome inhibitor. TSG101, involved in endosomal sorting, is regulated by proteasomal degradation. Epoxomicin enhances TSG101 activity by inhibiting proteasomes, preventing its degradation, and increasing its functional activity in mediating endosomal sorting processes. | ||||||
E-64 | 66701-25-5 | sc-201276 sc-201276A sc-201276B | 5 mg 25 mg 250 mg | $281.00 $947.00 $1574.00 | 14 | |
E64d is a cysteine protease inhibitor. TSG101 is susceptible to proteolytic degradation by cysteine proteases. E64d enhances TSG101 activity by inhibiting cysteine proteases, preventing TSG101 degradation, and increasing its functional activity in cellular processes related to endosomal sorting and protein trafficking. | ||||||
Concanamycin A | 80890-47-7 | sc-202111 sc-202111A sc-202111B sc-202111C | 50 µg 200 µg 1 mg 5 mg | $66.00 $167.00 $673.00 $2601.00 | 109 | |
Concanamycin A is a vacuolar ATPase inhibitor. TSG101 is involved in vacuolar trafficking processes. Inhibition of vacuolar ATPase by Concanamycin A enhances TSG101 activity by disrupting vacuolar functions, preventing its degradation, and increasing its functional activity in mediating cellular processes related to vacuolar trafficking. | ||||||
Eeyarestatin I | 412960-54-4 | sc-358130B sc-358130 sc-358130A sc-358130C sc-358130D sc-358130E | 5 mg 10 mg 25 mg 50 mg 100 mg 500 mg | $114.00 $203.00 $354.00 $697.00 $1363.00 $5836.00 | 12 | |
Eeyarestatin I is an inhibitor of endoplasmic reticulum-associated protein degradation (ERAD). TSG101 is involved in ERAD processes. Inhibition of ERAD by Eeyarestatin I enhances TSG101 activity by preventing its degradation within the ER, leading to increased functional activity in cellular processes associated with ERAD. | ||||||